Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
Jonathon W. Senefeld, Massimo Franchini, Carlo Mengoli, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2250647-e2250647
Open Access | Times Cited: 121

Showing 1-25 of 121 citing articles:

Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing
Mary K. Hayden, Ibrahim K El Mikati, Kimberly E. Hanson, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 57
A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
Daniele Focosi, Arturo Casadevall
Viruses (2022) Vol. 14, Iss. 9, pp. 1999-1999
Open Access | Times Cited: 50
Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
Evan M. Bloch, Daniele Focosi, Shmuel Shoham, et al.
Clinical Infectious Diseases (2023) Vol. 76, Iss. 11, pp. 2018-2024
Open Access | Times Cited: 35
SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
Arturo Casadevall, Daniele Focosi
Journal of Clinical Investigation (2023) Vol. 133, Iss. 6
Open Access | Times Cited: 31
Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
David J. Sullivan, Massimo Franchini, Jonathon W. Senefeld, et al.
Journal of General Virology (2023) Vol. 104, Iss. 5
Open Access | Times Cited: 30
Mortality Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis
Jonathon W. Senefeld, Ellen K. Gorman, Patrick W. Johnson, et al.
Mayo Clinic Proceedings Innovations Quality & Outcomes (2023) Vol. 7, Iss. 5, pp. 499-513
Open Access | Times Cited: 28
Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy
Arturo Casadevall, Michael J. Joyner, Liise-anne Pirofski, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 5, pp. 381-395
Closed Access | Times Cited: 25
Persistent COVID-19 in immunocompromised patients—Israeli society of infectious diseases consensus statement on diagnosis and management
Suzy Meijer, Yael Paran, Ana Belkin, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 8, pp. 1012-1017
Closed Access | Times Cited: 10
Safety and Efficacy of Convalescent Plasma Combined with Other Pharmaceutical Agents for Treatment of COVID-19 in Hospitalized Patients: A Systematic Review and Meta-Analysis
Massimo Franchini, Daniele Focosi, Mario Cruciani, et al.
Diseases (2024) Vol. 12, Iss. 3, pp. 41-41
Open Access | Times Cited: 8
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 8
Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: A prospective cohort study
Jorge Calderón‐Parra, Andrea Gutiérrez-Villanueva, Gerard Ronda-Roca, et al.
International Journal of Antimicrobial Agents (2024) Vol. 63, Iss. 3, pp. 107095-107095
Open Access | Times Cited: 7
Intravenous immunoglobulin therapy for COVID-19 in immunocompromised patients: A retrospective cohort study
Remigius Gröning, J Walde, Clas Ahlm, et al.
International Journal of Infectious Diseases (2024) Vol. 144, pp. 107046-107046
Open Access | Times Cited: 7
Convalescent plasma and predictors of mortality among hospitalized patients with COVID-19: a systematic review and meta-analysis
Massimo Franchini, Mario Cruciani, Carlo Mengoli, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 12, pp. 1514-1522
Closed Access | Times Cited: 7
Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study
Sammy Huygens, Corine H. GeurtsvanKessel, Arvind Gharbharan, et al.
Clinical Infectious Diseases (2024) Vol. 78, Iss. 6, pp. 1514-1521
Open Access | Times Cited: 6
COVID-19 clinical presentation, management, and epidemiology: a concise compendium
David P. Maison, Hawi Tasissa, Amelia N. Deitchman, et al.
Frontiers in Public Health (2025) Vol. 13
Open Access
Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials
Charalampos Filippatos, Ioannis Ntanasis‐Stathopoulos, Kalliopi Sekeri, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 765-765
Open Access | Times Cited: 16
Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein
Vinit Upasani, Katie Townsend, Mary Wu, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 7, pp. 950-960
Open Access | Times Cited: 15
Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial
Karine Lacombe, Thomas Hueso, Raphaël Porcher, et al.
BMJ Medicine (2023) Vol. 2, Iss. 1, pp. e000427-e000427
Open Access | Times Cited: 15
Antibody and B Cell Responses to SARS-CoV-2 Infection and Vaccination: The End of the Beginning
Katharina Röltgen, Scott D. Boyd
Annual Review of Pathology Mechanisms of Disease (2023) Vol. 19, Iss. 1, pp. 69-97
Open Access | Times Cited: 14
Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19
Juan G. Ripoll, Sidna M. Tulledge‐Scheitel, Anthony A. Stephenson, et al.
mBio (2024) Vol. 15, Iss. 5
Open Access | Times Cited: 5
Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce
Zachary Willis, Carlos R. Oliveira, Mark J. Abzug, et al.
Journal of the Pediatric Infectious Diseases Society (2024) Vol. 13, Iss. 3, pp. 159-185
Open Access | Times Cited: 4
Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report
Serena Vita, Alessandra D’Abramo, Andrea Coppola, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Estimates of Actual and Potential Lives Saved in the United States from the use of COVID-19 Convalescent Plasma
Quigly Dragotakes, Patrick W. Johnson, Matthew R. Buras, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma
Quigly Dragotakes, Patrick W. Johnson, Matthew R. Buras, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 41
Open Access | Times Cited: 4
Molnupiravir: From Hope to Epic Fail?
Daniele Focosi
Viruses (2022) Vol. 14, Iss. 11, pp. 2560-2560
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top